Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-20
    E.g., 2018-09-20

Archive Search

Pages

21 results
11:02 AM, Mar 12, 2018  |  BioCentury | Regulation

Stretching accelerated approval

study examined Eli Lilly and Co.’s Lartruvo olaratumab, a human IgG1 mAb targeting platelet derived growth factor
12:00 AM, Oct 13, 2014  |  BioCentury | Regulation

The lung haul

nintedanib is a small molecule inhibitor of multiple pro-angiogenic kinases, including VEGF receptor, platelet derived growth factor
PDGF) receptor and fibroblast growth factor (FGF) receptor . The PDUFA date is undisclosed. Vargatef also is …
integrin alpha(V)beta(6) ; and FibroGen Inc. 's FG-3019 , a humanized mAb against connective tissue growth factor
12:00 AM, Oct 13, 2014  |  BioCentury | Regulation

The lung haul

nintedanib is a small molecule inhibitor of multiple pro-angiogenic kinases, including VEGF receptor, platelet derived growth factor
PDGF) receptor and fibroblast growth factor (FGF) receptor . The PDUFA date is undisclosed. Vargatef also is …
integrin alpha(V)beta(6) ; and FibroGen Inc. 's FG-3019 , a humanized mAb against connective tissue growth factor
12:00 AM, Jul 15, 2013  |  BioCentury | Regulation

Coding for utility

marker for cancer. The company developed the CertNDx Bladder Cancer Assay, which combines MMP2, fibroblast growth factor
For example, on July 10 Palmetto announced it will not cover tests for vascular endothelial growth factor
12:00 AM, Dec 19, 2011  |  BioCentury | Regulation

IQWiG spells surprise

necrosis factor (TNF) alpha and IL-1 beta, as well as pro-fibrotic cytokines, including platelet derived growth factor
PDGF) and transforming growth factor (TGF) beta. In 2009, InterMune reported Esbriet met the primary endpoint of …
12:00 AM, Jul 11, 2011  |  BioCentury | Regulation

Looking beyond Avastin

Merck & Co. Inc. (NYSE:MRK) Ridaforolimus/dalotuzumab Small molecule mTOR inhibitor plus humanized mAb against insulin-like growth factor-1 …
5 (DR5) Ph II Eli Lilly and Co. (NYSE:LLY) IMC-18F1 Human mAb against vascular endothelial growth factor
Co. (NYSE:LLY)/ Bristol-Myers Squibb Co. (NYSE:BMY)/Merck KGaA (Xetra:MRK) Erbitux cetuximab Chimeric IgG1 mAb targeting epidermal growth factor
12:00 AM, Dec 20, 2010  |  BioCentury | Regulation

Label: No; Access: Yes

trials." According to a Roche presentation titled "The Quest for Angiogenesis Biomarkers," VEGF, platelet derived growth factor
PDGF), basic fibroblast growth factor (bFGF); vascular cell adhesion molecule-1 (VCAM-1) , matrix metalloproteinase 1 (MMP-1) and …
12:00 AM, Aug 23, 2010  |  BioCentury | Regulation

Run off the road

neuralgia(PHN)]; Ph III [neuropathic pain; post-operative pain] Pfizer Inc. (NYSE:PFE) Tanezumab (PF-4383119) mAb against nerve growth factor
12:00 AM, May 31, 2010  |  BioCentury | Regulation

Cutting the VAT

link. The panel also was concerned by an increase in insulin resistance and elevated insulin-like growth factor-1 …
downstream of growth hormone, the company expected to see an increase in levels of the growth factor
12:00 AM, Oct 12, 2009  |  BioCentury | Regulation

Cancer Trade-offs

treatment. Votrient, like Sutent and Nexavar, inhibits multiple tyrosine kinases, including VEGF and platelet derived growth factor

Pages